http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
박선양(Seon Yang Park),계경채(Kyung Chae Kye),김병국(Byoung Kook Kim),김노경(Noe Kyeong Kim),이문호(Moon Ho Lee),이규섭(Kye Sup Lee),박문규(Moon Kye Park),박근조(Keun Jo Park) 대한내과학회 1989 대한내과학회지 Vol.36 No.2
N/A It has been suggested that impaired fibrinolysis plays a role in the development of deep vein thrombosis. The net fibrinolytic activity of blood is dependent on the sum of different types of plasminogen activators (PAs) and plasminogen activator inhibitors (PAIs). Therefore, assessment of each component of the fibrinolytic system is important in order to understand the underlying basis of thrombotic disorders. Certain pathological conditions may exhibit elevated plasma PAI which may inactivate endogenous PA by forming PA-PAI complexes. These enzymatically inactive complexes will not be detected by most functional assays. As PAs released into the circulation are captured within minutes by the excess of PAIs, it is reasonable to assume that PAIs may play an important role in regulating the activity of PAs, and hence the net fibrinolytic activity of the blood. Among the different forms of PAIs, PAI-1 synthesizd and secreted by the endothelial cells and found in the platelets has been suggested to play a major role in the regulation of fibrinolytic activity of the blood. For these reasons, we developed an enzyme-linked immunosorbent assay specific of human PAI-1 and measured its plasma levels in normal Korean subjects and in patients with deep vein thrmbosis. 1) Our ELISA for PAI-l measured both the free PAI-1 and u-PA-PAI-1 complexes. 2) The PAI-1 concentration of our PAI-1 standard, a conditioned medium of cultured human umbilical vein endothelial cells, was 257 ng/ml. 3) The PAI-1 concentrations of EDTA plasma in 16 normal Korean subjects ranged from 0-12,8 ng/ ml (4. 8+ 3.4 ng/ml). 4) The plasma PAI-1 levels in 13 patients with deep vein thrombosis were elevated to 2.8-38.4 ng/ml (16.6+ 9.8 ng/ml). This difference was statistically significant when compared to normal subjects (p<0.001). 5) With a cut-off value of 15.0 ng/ml (up to 3 SD from the mean) for normal plasma PAI-1 concentrations, 6 of the 13 patients (46.2%) with deep vein thrombosis were found to have elevated PAI-1 levels in their plasma, while all the normal subjects had their plasma PAI-1 levels in the normal range.
마우스 태생간 조혈세포이식시 이식거부 반응을 극복하기 위한 조혈세포 용량 및 흉선세포의 역할에 관한 연구
김승택(Seung Taik Kim),박선양(Seon Yang Park),김병국(Byong Kook Kim),이홍복(Hong Bock Lee),김은실(Eun Shik Kim),계경채(Kyung Chae Kye),서정선(Jeong Sun Seo),강위생(Wee Saing Kang),이현순(Hyun Soon Lee),궁성수(Sung Soo Koong),이재훈(J 대한내과학회 1990 대한내과학회지 Vol.39 No.5
N/A To observe whether an increase in cell doses can overcome graft rejection, whether sustained chimerism is present, and whether fetal thymic cell transplantation has any effect on the survival and the cell dose needed, fetal liver transplantation was done from 17-18-day old DDY fetus to an ICR mouse (syngeneic transplantationl) previously irradiated. The results revealed that better survival was obtained, regardless of syngeneic of allogeneic fetal liver cell transplantion, through an increase of the cell dose. A 90F long- term survial was noticed with a cell dose of 15×108/kg in syngeneic transplantation. In the case of allogeneic transplantation, however, only a 50% long - term survival rate was observed with the same dose. The concurrent thymic cell transplantation had a good effect on the long - term survival and the reduction of cell dose required, The cell dose needed for the achievement of a 90% long - term survival in syngeneic and allogeneic transplantation was 5x108/kg and 15x108/kg, respectively The sustained chimerism was evident and the graft-versus-host disease was mininal in fetal liver cell transplantation. It was evident that fetal liver cell transplantation could be one of substitution in solving the problems of bone marrow transplantation The cell dose required to prevent graft failure decreased with fetal thymic cell transplantation The mechanism of the salutary effect of concurrent thymic cell transplantation is not yet to be elucidated.
이진학(Jin Hak Lee),김노경(Noe Kyeong Kim),김병국(Byoung Kook Kim),양성현(Sung Hyun Yang),신현춘(Hyun Choon Shin),계경채(Kyung Chae Kye),박선양(Seon Yang Park) 대한내과학회 1994 대한내과학회지 Vol.47 No.3
N/A Background: Antiphospholipid syndrome is characterized by arterial or venous thrombosis, recurrent fetal loss, thrombocytopenia, and presence of antiphospholipid antibody. This study was done to know the clinical and serological characteristics of antiphospholipid syndrome in Korea and to evaluate the therapeutic efficacy of prednisolone and antithrombotic agents in antiphospholipid syndrome. Methods: Clinical and laboratory features of 11 patients with antiphospholipid antibodies and histories of spontaneous abortion and thrombosis were studied. Results: Of the 11 patients, 3 were male, and 8 were female, and the ages ranged from 19 to 54 years (median, 30). 3 patients had systemic lupus erythematosus, and the other 8 fulfilled criteia for the primary antiphospholipid syndrome. Initial presentations were deep vein thrombosis in 4 patients, spontaneous abortion in 4, pulmonary embolism in 1, splenic infarct in 1, and stroke in 1. Seven of 11 patents (63.6%) had episodes of venous thrombosis, and in 2 these were accompanied by pulmonary embolism. Arterial occlusions were present in 2 patients. These comprised splenic infarct and right middle cerebral arterial occlusion. Splenic infarct was accompanied by portal vein, splenic vein, and superior mesenteric vein thrombosis. Spontaneous abortion were present in 6 patients with wide range of episodes of fetal loss (range 1-6, median 2.5). Six episodes of spontaneous abortion occurred during the second trimester and 6 during the third. Combined diseases were idiopathic thrombocytopenic purpura, liver chirrosis, iron deficiency anemia, hypertension, and mitral regurgitation. Six patients had both the lupus anticoagulant and anticardiolipin antibodies; 2 had anticardiolipin antibodies alone; and 3 had only the lupus anitcoagulant. Antinuclear antibodies (>1:40) were present in 8 of the 11 patients and anti-ds-DNA (>25 units) in 3. False positive VDRLs were noted in 3 patients, and thrombocytopenia (<150,000/mm) in 6. Two of three pregnancy ended with normal live birth after adminstration of prednisolone and aspirin, and all thrombotic episodes were resolved with prednisolone plus heparine/warfarin or prednisolone plus aspirin or heparine/warfarin alone. Conclusions: The clinical and serological features of the antiphospholipid syndrome in korea were similar to those of previous reports. Prednisolone and antithrombotic agents were effective in these patients, especially in those who had been suffering from spontaneous abortions.
류마티 질환에서 항 Cardiolipin 항체의 출현 빈도와 임상적 의의
송영욱,계경채,박선양,최강원 대한내과학회 1990 대한내과학회지 Vol.38 No.5
We analyzed the frequency and clinical significance of serum anticardiolipin antibodies by enzyme linked immunosorbent assay in 67 patients with various rheumatic diseases. A significantly elevated frequency of anticardiolipin antibody was found in patients with systemic lupus erythematosus(44%), rheumatoid arthritis(39%) and dermatomyositis(20%). None of the patients with progressive systemic sclerosis had anticardiolipin antibody. In the case of SLE, the anticardiolipin antibody level seemed to parallel the disease activity. Along with clinical improvement, the anticardiolipin antibody and anti-ds DNA antibody level decreased, while the serum complement increased. The presence of anticardiolipin antibody correlated with elevated ESR and positive Coombs' test in patients with systemic lupus erythematosus. These results suggest that the anticardiolipin antibody levels reflect disease activity and that some anticardiolipin antibody may be capable of recognizing a phospholipid epitope on the surface of the red blood cell. No significant association was found between the anticardiolipin antibody and the rheumatoid factor or the antinuclear antibody in patients with rheumatoid arthritis. There was no significant association between the anticardiolipin antibody and skin rash, Raynaud's phenomenon, antinuclear antibody or the rheumatoid factor in patients with dermatomyositis.